A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Atezolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms TAIL
- Sponsors Roche
- 06 Jun 2023 Results of exploratory post hoc analysis (n=57) assessing the baseline autoantibody profiles and its correlation with efficacy and safety outcomes in NSCLC pts with either pre-existing AID or who had prior ICI therapy and received atezolizumab presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 25 May 2022 Status changed from active, no longer recruiting to completed.
- 18 May 2022 This trial has been completed in Poland (end of the trial : 23 Mar 2018), according to European Clinical Trials Database record.